Home » RegeneRx Receives Mexican Patent for the Use of TB4 for Prevention, Treatment of Cardiac Damage
RegeneRx Receives Mexican Patent for the Use of TB4 for Prevention, Treatment of Cardiac Damage
RegeneRx Biopharmaceuticals, Inc. announced Thursday that the Company received a patent from the Mexico Patent and Trademark Office for the use of thymosin beta 4, its analogues, isoforms, and other derivatives, for preventing or healing the damage that occurs from a myocardial event, or heart attack.
TheStreet
TheStreet
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May